Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage.
Pflugers Arch
; 474(10): 1069-1076, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-1955965
ABSTRACT
Proinflammatory cytokines target vascular endothelial cells during COVID-19 infections. In particular, the endothelial glycocalyx (eGC), a proteoglycan-rich layer on top of endothelial cells, was identified as a vulnerable, vasoprotective structure during infections. Thus, eGC damage can be seen as a hallmark in the development of endothelial dysfunction and inflammatory processes. Using sera derived from patients suffering from COVID-19, we could demonstrate that the eGC became progressively worse in relation to disease severity (mild vs severe course) and in correlation to IL-6 levels. This could be prevented by administering low doses of spironolactone, a well-known and highly specific aldosterone receptor antagonist. Our results confirm that SARS-CoV-2 infections cause eGC damage and endothelial dysfunction and we outline the underlying mechanisms and suggest potential therapeutic options.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Spironolactone
/
Glycocalyx
/
Mineralocorticoid Receptor Antagonists
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Pflugers Arch
Year:
2022
Document Type:
Article
Affiliation country:
S00424-022-02726-3
Similar
MEDLINE
...
LILACS
LIS